Ovarian cancer is a common gynecological malignancy, and its treatment remains
challenging. Although ovarian cancer may respond to immunotherapy because of …

Numerous preclinical studies have demonstrated the inhibitory function of T cell
immunoglobulin mucin domain-containing protein 3 (Tim-3) on T cells as an inhibitory …

Nuclear factors TOX and TOX2 upregulate TIM3 expression and lead to T-cell exhaustion in
malignancies. Here, we demonstrate two distinct TIM3 expression patterns (high & low) with …

T cell immunoglobulin and mucin domain-3 (TIM-3), a crucial immune checkpoint following
PD1 and CTLA4, is widely found in several immune cells. Nonetheless, its performance in …

A steady dysfunctional state caused by chronic antigen stimulation in the tumor
microenvironment (TME) is known as CD8+ T cell exhaustion. Exhausted-like CD8+ T cells …

Cancer immunotherapy, leveraging antibodies, excels in targeting efficacy but faces hurdles
in tissue penetration, oral delivery, and prolonged half-life, with costly production and risk of …

Immunotherapy has changed the treatment landscape for patients with cancer in the past
decade. Immune checkpoint inhibitor (ICI)-based therapies have proven effective in a range …

As immune-checkpoint inhibitors (ICIs) therapy has made great strides in hepatocellular
carcinoma (HCC) treatment, improving patient response to this strategy has become the …

The advent of immune checkpoint inhibitors (ICIs) in colorectal cancer (CRC) treatment
marks a major breakthrough. These therapies have proven safer and more effective than …

Recent studies have demonstrated that β-catenin in dendritic cells (DCs) serves as a key
mediator in promoting both CD4 and CD8 T cell tolerance, although the mechanisms …